To investigate the relationship between the expression of ERCC1 and/or DDB2 and the clinical effect of DCS therapy, we examined the expression of these proteins in tumor tissues before treatment by immunohistochemistry and analyzed the correlation with the anti-tumor effect (pathological response) of DCS therapy. This evidence concerns the gene DDB2 and neoplasm.